NASDAQ:ACOR Shareholder Alert: Investigation over Possible Securities Laws Violations by Acorda Therapeutics Inc

An investigation for investors in Acorda Therapeutics Inc (NASDAQ:ACOR) shares over potential securities laws violations by Acorda Therapeutics was announced.

Logo

San Diego, CA -- (SBWire) -- 09/18/2017 --An investigation on behalf of investors of Acorda Therapeutics Inc shares over potential securities laws violations was announced.

Investors who purchased shares of Acorda Therapeutics Inc (NASDAQ:ACOR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Acorda Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On August 29, 2017, Acorda Therapeutics Inc disclosed that it had received a Refusal to File ("RTF") letter from the U.S. Food and Drug Administration ("FDA") regarding the new drug application ("NDA") it had submitted in June for Inbrija, a potential treatment for Parkinson's disease. Acorda Therapeutics Inc stated, "FDA specified two reasons for the RTF: first, the date when the manufacturing site would be ready for inspection, and, second, a question regarding the submission of the drug master production record."

Those who purchased shares of Acorda Therapeutics Inc (NASDAQ:ACOR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

Media Relations Contact

Michael Daniels
General Manager
Shareholders Foundation
858-779-1554
http://www.ShareholdersFoundation.com

View this press release online at: http://rwire.com/866191